Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study

被引：0

作者：

Qing Zhou

He-Long Zhang

Li-Yan Jiang

Yuan-Kai Shi

Yuan Chen

Jin-Ming Yu

Cai-Cun Zhou

Yong He

Yan-Ping Hu

Zong-An Liang

Yue-Yin Pan

Wen-Lei Zhuo

Yong Song

Gang Wu

Gong-Yan Chen

You Lu

Cui-Ying Zhang

Yi-Ping Zhang

Ying Cheng

Shun Lu

Chang-Li Wang

Jian-Ying Zhou

Yun-Peng Liu

Jian-Xing He

Jie Wang

Yi-Long Wu

机构：

[1] Guangdong Provincial People’s Hospital,Guangdong Lung Cancer Institute

[2] Guangdong Academy of Medical Sciences,Department of Oncology

[3] Tangdu Hospital,Department of Respiratory Medicine

[4] Fourth Military Medical University,Department of Medical Oncology

[5] Shanghai Chest Hospital,Department of Oncology

[6] Shanghai Jiao Tong University,Department of Radiation Oncology

[7] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical Oncology

[8] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Respiratory Medicine

[9] Tongji Hospital of Tongji Medical College,Department of Oncology

[10] Huazhong University of Science and Technology,Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital

[11] Shandong Cancer Hospital Affiliated to Shandong University,Department of Oncology

[12] Shandong Academy of Medical Sciences,Department of Oncology

[13] Shanghai Pulmonary Hospital,Department of Respiration

[14] Tongji University,Cancer Center, Tongji Medical College

[15] Daping Hospital and the Research Institute of Surgery of the Third Military Medical University,Department of Respiration

[16] Hubei Cancer Hospital,Department of Thoracic Oncology, Cancer Center

[17] Sichuan University,Cancer Center

[18] Anhui Medical University,Department of Thoracic Medical Oncology

[19] Xinqiao Hospital,Department of Oncology

[20] The Third Military Medical University,Department of Shanghai Lung Cancer Center

[21] General Hospital of Eastern Theater Command of Chinese People’s Liberation Army,Department of Lung Cancer

[22] Union Hospital,Department of Respiratory Disease, Thoracic Disease Center, First Affiliated Hospital of College of Medicine

[23] Huazhong University of Science and Technology,Department of Medical Oncology

[24] Harbin Medical University Cancer Hospital,Department of Thoracic Surgery, Guangzhou Institute for Respiratory Health

[25] West China Hospital,undefined

[26] Sichuan University,undefined

[27] Inner Mongolia Autonomous Region People’s Hospital,undefined

[28] Zhejiang Cancer Hospital,undefined

[29] Jilin Cancer Hospital,undefined

[30] Shanghai Chest Hospital,undefined

[31] Shanghai Jiaotong University,undefined

[32] Tianjin Medical University Cancer Institute and Hospital,undefined

[33] Zhejiang University,undefined

[34] The First Hospital of China Medical University,undefined

[35] First Affiliated Hospital of Guangzhou Medical University,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷

关键词：

Epidermal growth factor receptor; T790M; Non-small cell lung cancer; Osimertinib; Real-world;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：10771 / 10780

页数：9

共 50 条

[21] The impact of age and performance status on the efficacy of osimertinib in patients with EGFR T790M-positive non-small cell lung cancer
Gil, Hyun-Il
Um, Sang-Won
JOURNAL OF THORACIC DISEASE, 2020, 12 (03) : 153 - 155
[22] Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M-positive non-small cell lung cancer
Kim, Hye Sook
Lim, Kun Young
Lee, Soo-Hyun
Kim, Hyae Young
Lee, Youngjoo
Han, Ji-Youn
CANCER MEDICINE, 2023, 12 (11): : 12285 - 12298
[23] Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis
Hirashima, Tomonori
Satouchi, Miyako
Hida, Toyoaki
Nishio, Makoto
Kato, Terufumi
Sakai, Hiroshi
Imamura, Fumio
Kiura, Katsuyuki
Okamoto, Isamu
Kasahara, Kazuo
Uchida, Hirohiko
Vowler, Sarah L.
Mitsudomi, Tetsuya
CANCER SCIENCE, 2019, 110 (09) : 2884 - 2893
[24] ASTRIS, a real-world study with osimertinib in patients with non-small cell lung cancer (NSCLC) EGFR T790M mutated: Characteristics and diagnostic methods used for patients included in Spain
Vicente Baz, D.
Paredes Lario, A.
Moran Bueno, M. T.
Massuti Sureda, B.
Reguard, N.
Alvarez, R.
Insa Molla, A.
Juan, O.
Marquez, G.
Provencio Pulla, M.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S93 - S94
[25] Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
Eide, Inger Johanne Zwicky
Helland, Aslaug
Ekman, Simon
Mellemgaard, Anders
Hansen, Karin Holmskov
Cicenas, Saulius
Koivunen, Jussi
Gronberg, Bjorn Henning
Brustugun, Odd Terje
LUNG CANCER, 2020, 143 : 27 - 35
[26] Osimertinib effective in EGFR T790M-positive lung cancer
Mayor, Susan
LANCET ONCOLOGY, 2017, 18 (01): : E9 - E9
[27] The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib
Buder, Anna
Hochmair, Maximilian J.
Filipits, Martin
TARGETED ONCOLOGY, 2021, 16 (01) : 77 - 84
[28] Real-World Safety and Efficacy Data of Osimertinib in Patients from Japan with EGFR T790M-Positive NSCLC
Ohe, Y.
Kato, T.
Shimizu, W.
Sakamoto, K.
Sugeno, M.
Tamura, R.
Tokimoto, T.
Gemma, A.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S852 - S852
[29] Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study
Cao, Y.
Qiu, X.
Xiao, G.
Hao, H.
ANNALS OF ONCOLOGY, 2017, 28
[30] The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib
Anna Buder
Maximilian J. Hochmair
Martin Filipits
Targeted Oncology, 2021, 16 : 77 - 84

← 1 2 3 4 5 →